Medregen, LLC

Johns Hopkins University

Zhaoli Sun

George Melville Williams

Jun O Liu

Jingxin Wang

Xuhang Li

Zufeng Guo

Sam Hong

Qing Lin

Isaac Agyemang

Mitchell Williams

Richard Brewer

Zhimin Liu

Rachel Labell

Christy Eatmon

John Sun

Jun Liu

Hanjing Peng

Ali Ahmadi

Le Qi

Yuefan Wang

Brandon J Peiffer

Embodiments of the disclosure relate generally to formulations, methods, kits, and dosage forms for improved stability comprising at least two active ingredients, AMD3100, or similar stem cell mobilizer, and Tacrolimus, or FK506 derivative or analog, and one or more excipients. The formulations may be administered as a single dose subcutaneous injection. The formulations may be useful in treating various diseases, disorders or injuries.

Formulations, methods, kits, and dosage forms

The present invention relates to the field of wound healing. More specifically, the present invention provides methods and compositions useful for improved wound healing via autologous stem cell mobilization. In one embodiment, a method for improving wound healing in a patient comprises administering to the patient a therapeutically effective amount of a stem cell mobilizer and a low dose of an immunosuppressive agent.

Methods of recruiting SDF-producing macrophages

A compound of Formula I, and its analogs are provided. Compositions that include Formula I can be used to inhibit human equilibrative nucleoside transporter 1, increase adenosine signaling and produce effects that include increasing antiviral activity, increasing antiparasitic activity, increasing alcohol tolerance, decreasing pain protecting from ischemia as well as many other conditions.

Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof

The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34and/or CD133stem cells and a low dose of an immunosuppressive agent.

Methods of treating inflammatory bowel disease with AMD3100 and Tacrolimus

The present invention relates to the field of organ transplantation. In one aspect, the present invention provides methods of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.

Treatment methods utilizing stem cell mobilizers and immunosuppressive agents

A compound of Formula (I), and its analogs are provided. Compositions that include Formula I can be used to inhibit human equilibrative nucleoside transporter 1, increase adenosine signaling and produce effects that include increasing antiviral activity, increasing antiparasitic activity, increasing alcohol tolerance, decreasing pain protecting from ischemia as well as many other conditions. 

Methods of treating inflammatory bowel disease with AMD3100 and tacrolimus

Growing community of inventors

Perry Hall, MD, United States of America

Zhaoli Sun